Of note, our previous in vitro and ex vivo work targeting PANX1 in melanoma employed murine B16‐F0, B16‐F1, B16‐F10, and human BRAF(V600E)‐mutant melanoma cell lines (A375‐P and A375‐M2) that do not entirely share the same genomic alterations of the BPC model [15, 41]. The gene discussed is BRAF; the disease is melanoma.